Common adverse reactions of Momelotinib and daily management precautions

Momelotinib is an oral JAK1/JAK2 tyrosine kinase inhibitor mainly used to treat patients with myelofibrosis (MF), especially moderate to severe patients with anemia or thrombocytopenia. By inhibiting the abnormally activated JAK-STAT signaling pathway, it reduces the secretion of pro-inflammatory cytokines, improves symptoms related to myelofibrosis, and has a certain alleviating effect on anemia and splenomegaly. Although the efficacy of molotinib is accurate, there are still many adverse reactions in clinical application. Reasonable daily management is crucial to ensure the efficacy, reduce complications and improve patients' quality of life.
Hematological adverse reactions are one of the most common adverse events of molotinib, including anemia, thrombocytopenia and neutropenia. Some patients may experience a decrease in hemoglobin or platelet count in the early stages of treatment, which is mainly related to the temporary decrease in bone marrow hematopoietic function caused by the inhibition of the JAK2 signaling pathway. Blood routine should be monitored regularly in daily management, especially hemoglobin, white blood cells and platelet levels should be reviewed weekly or every two weeks within 4 to 8 weeks before treatment. For patients with mild to moderate anemia, iron, folic acid or erythropoiesis stimulating agents can be used to assist in improvement; in cases of severe thrombocytopenia or neutropenia, the dosage of molotinib should be adjusted or temporarily discontinued as directed by the doctor, while preventing the risk of infection and bleeding.

Adverse reactions related to liver function and metabolism are also common in some patients. Molotinib is metabolized by the liver and may cause an increase in transaminases or a mild increase in bilirubin. In daily management, baseline liver function evaluation should be performed before treatment, and liver function should be reviewed every 1–2 months during medication. When there is a significant increase, the dose should be adjusted in time or the administration should be interrupted, and the concomitant use of hepatotoxic drugs, such as some antifungals, antituberculosis drugs and certain antibiotics, should be avoided. At the same time, excessive drinking and high-fat diet should be avoided to reduce the burden on the liver.

Gastrointestinal and digestive system adverse reactions are common non-hematological adverse reactions of molotinib, manifesting as nausea, vomiting, diarrhea, loss of appetite or mild abdominal pain. For daily management, it is recommended that patients adopt the principle of eating small amounts frequently and a light diet, and avoid fried, spicy and irritating foods. You can take anti-nausea drugs, such as metoclopramide or oseltamivir, under the guidance of a physician, while maintaining adequate fluid intake to avoid dehydration. If symptoms persist or worsen, you should seek medical advice promptly to assess whether dosage adjustment or temporary discontinuation is needed.
Nervous system and cardiovascular-related adverse reactions include headache, dizziness, fatigue and mild decrease in blood pressure. Patients should avoid standing up suddenly or changing positions quickly in daily life to reduce the risk of orthostatic hypotension; when obvious fatigue or dizziness occurs, high-risk activities, such as driving or operating machinery, should be suspended. At the same time, patients are advised to maintain a regular schedule, exercise moderately, and monitor blood pressure and heart rate. In some studies, molotinib may have a mild effect on the QT interval, so drug interactions should be paid attention to when taking concurrent medications, and electrocardiogram monitoring should be performed if necessary.
In addition, skin and systemic reactions, such as mild rash, pruritus, or peripheral edema, also need attention. Daily management includes using mild skin care products, avoiding prolonged immersion in hot water and wearing tight clothing. If severe rash or allergic symptoms occur, you should stop taking the medicine and seek medical advice promptly. For systemic symptoms, such as low fever, fatigue, weight loss, etc., attention should be paid to nutritional support and psychological intervention to improve patients' quality of life and medication compliance.
In conclusion, molotinib has unique efficacy in the treatment of myelofibrosis, especially in patients with anemia and splenomegaly. However, its adverse reactions involve many aspects such as hematology, liver function, gastrointestinal tract, cardiovascular and nervous system, and need to be effectively managed through regular monitoring, reasonable diet, lifestyle intervention and individualized dose adjustment. Patients should use medications scientifically under the guidance of doctors, pay close attention to changes in symptoms, and report abnormalities in a timely manner to ensure maximum efficacy, reduce drug-related risks, and achieve long-term safe treatment.
Reference: https://www.drugs.com/